How to Get Enclomiphene Citrate in California

What Enclomiphene Citrate Is and Why It Differs from Clomiphene

Enclomiphene citrate is the trans-isomer of clomiphene citrate. Clomiphene, sold as Clomid, is a 50/50 racemic mixture of the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene). Zuclomiphene has a long tissue half-life and may contribute to visual side effects and estrogenic activity; enclomiphene alone carries a shorter half-life and a cleaner receptor-antagonist profile at the hypothalamus 1.

By blocking hypothalamic estrogen receptors, enclomiphene raises gonadotropin-releasing hormone (GnRH) pulse frequency. That triggers pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then stimulate testicular testosterone production while preserving spermatogenesis 2. This mechanism separates it from exogenous testosterone replacement therapy (TRT), which suppresses the hypothalamic-pituitary-gonadal (HPG) axis and typically reduces sperm counts 3.

Kim et al. (BJU International, 2016, N=124) found that enclomiphene 12.5 mg and 25 mg daily raised serum testosterone to levels above 300 ng/dL in men with secondary hypogonadism, with mean testosterone increases of approximately 150 ng/dL over 12 weeks, while LH and FSH remained within normal range 4. Sperm concentration was preserved or improved in all active treatment arms. No commercially approved single-isomer enclomiphene product currently holds an active NDA with the FDA 5.

The Legal Status of Enclomiphene Citrate in California

Enclomiphene citrate is a prescription-only compound in California. It is not a controlled substance under the DEA schedules or under California Health and Safety Code section 11054-11058 6. Because no finished pharmaceutical product holds FDA approval for enclomiphene as a standalone drug, all dispensing in California occurs through state-licensed 503A compounding pharmacies operating under United States Pharmacopeia (USP) Chapter 795 standards 7.

California's Business and Professions Code section 4126 requires that a valid patient-specific prescription exist before a 503A pharmacy compounds and dispenses. The California State Board of Pharmacy enforces these standards and licenses each compounding facility independently 8. Prescriptions written by out-of-state providers are not valid for dispensing within California; the prescriber must hold an active California license or a California telehealth registration 9.

Who Can Prescribe Enclomiphene Citrate in California

Any California-licensed prescriber with authority to prescribe legend drugs may write a valid enclomiphene order. That includes MDs, DOs, nurse practitioners (NPs) with furnishing authority, and physician assistants (PAs) supervising under a Physician and Surgeon 10. California Business and Professions Code section 2836.1 grants certified NPs independent prescribing rights after completing the required experience hours and a standardized procedures agreement or, under AB 890 (effective 2023), full practice authority in approved settings 11.

PAs in California may prescribe under a delegation order from a supervising physician. Telehealth-based prescribers must comply with California Business and Professions Code section 2290.5, which mandates that the standard of care be equivalent to in-person care 12. A prescriber who has not established a legitimate patient-provider relationship through a synchronous video visit or documented asynchronous evaluation cannot legally issue a compounded enclomiphene prescription in California.

Labs Required Before a California Prescriber Will Issue the Prescription

A California clinician will not prescribe enclomiphene without objective evidence of secondary hypogonadism. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies that a diagnosis requires at least two morning serum total testosterone measurements below 300 ng/dL, drawn before 10:00 AM on separate days, combined with signs or symptoms of androgen deficiency 13. Secondary hypogonadism is confirmed when those low testosterone levels are accompanied by low or inappropriately normal LH and FSH, indicating a pituitary or hypothalamic cause rather than primary testicular failure.

The standard pre-treatment lab panel in California clinical practice includes:

• Total testosterone (two morning draws, separate days)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH
• Estradiol (sensitive LC-MS/MS assay preferred)
• Prolactin (to exclude pituitary adenoma)
• Complete blood count (CBC)
• Comprehensive metabolic panel (CMP)
• Thyroid-stimulating hormone (TSH)
• PSA if the patient is 40 years or older

LabCorp and Quest Diagnostics both operate draw sites throughout California. Most telehealth providers send a requisition directly to a nearby patient service center; results typically return within 48 to 72 hours. Some providers accept recent labs (drawn within 90 days) to avoid redundant draws 14. Providers following the American Urological Association (AUA) 2018 guideline on evaluation and management of testosterone deficiency require follow-up testosterone at 3 to 6 weeks after initiating therapy to confirm response 15.

How to Get a Prescription Through a California Telehealth Provider

Telehealth prescribing of enclomiphene in California is legal and widely practiced. California law does not require an in-person visit before prescribing a non-controlled compounded medication, provided the provider establishes a valid patient-provider relationship via synchronous audio-video 16. The standard process at most California telehealth platforms follows these steps:

Step 1. Online intake. The patient completes a medical history questionnaire covering symptoms (fatigue, low libido, poor morning erections, reduced muscle mass), current medications, and any prior hormone therapy. This typically takes 10 to 15 minutes.

Step 2. Lab order. The provider sends a laboratory requisition to LabCorp, Quest, or a local draw site. The patient completes the draw, ideally before 10:00 AM on a weekday.

Step 3. Synchronous video visit. Once lab results return (48 to 72 hours in most cases), the provider schedules a video consultation. The visit lasts 20 to 30 minutes and covers diagnosis, treatment goals, fertility considerations, and risk disclosure.

Step 4. Prescription issuance. If labs and history support secondary hypogonadism, the provider transmits an e-prescription directly to the patient's chosen California-licensed 503A compounding pharmacy.

Step 5. Pharmacy verification and dispensing. The pharmacy calls or messages the patient to confirm shipping address, payment, and any allergy concerns. Most California compounding pharmacies ship within 3 to 7 business days of receiving a verified prescription.

Response monitoring under most protocols calls for a repeat testosterone, LH, FSH, and estradiol panel at 4 to 6 weeks. If serum testosterone remains below 400 ng/dL, the prescriber may increase the dose from 12.5 mg to 25 mg daily 17. Prolactin and CBC are typically repeated at 3 months 18.

California 503A Compounding Pharmacies and Enclomiphene Citrate

Because no FDA-approved enclomiphene single-isomer tablet exists on the commercial market, every dispensed unit in California is compounded by a 503A pharmacy. A 503A pharmacy operates under state Board of Pharmacy licensure and compounds patient-specific prescriptions, unlike a 503B outsourcing facility that may produce larger batches without individual prescriptions 19.

California-licensed 503A pharmacies must follow USP 795 standards for non-sterile preparations, which govern raw material testing, beyond-use dating, environmental monitoring, and label requirements 20. Enclomiphene citrate is typically dispensed as:

• Oral capsules (12.5 mg or 25 mg, most common)
• Oral tablets pressed with microcrystalline cellulose base
• Sublingual troches (less common, variable bioavailability data)

Patients should confirm the pharmacy holds a current California Board of Pharmacy compounding license and that the API (active pharmaceutical ingredient) supplier provides a certificate of analysis (COA) for each lot. Reputable pharmacies will share these documents on request 21. A 30-day supply of enclomiphene 12.5 mg to 25 mg at a California compounding pharmacy typically costs $80 to $160 out of pocket, depending on dose and capsule count.

Medi-Cal Coverage and Prior Authorization Requirements

Medi-Cal (California Medicaid) covers compounded enclomiphene for secondary hypogonadism with prior authorization (PA). The prescriber must document that the patient meets diagnostic criteria for secondary hypogonadism per Endocrine Society guidelines, that at least two morning testosterone measurements fell below 300 ng/dL, and that an FDA-approved alternative (such as clomiphene citrate, generic) was considered or tried 22.

The PA submission typically includes:

• Completed Medi-Cal prior authorization request form (TAR or electronic equivalent)
• Two dated lab results showing low testosterone with LH/FSH values
• Prescriber attestation of secondary (not primary) hypogonadism
• ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) as appropriate
• Documentation of clinical signs and symptoms

Medi-Cal decisions on non-urgent PA requests must come within 5 business days under California law 23. Denials may be appealed through the Medi-Cal Fair Hearing process. Patients with commercial insurance should check their plan's specialty drug or compound benefit tier, as coverage for compounded preparations varies significantly across California PPO and HMO plans.

Transferring an Existing Prescription to California

Men who received an enclomiphene prescription from a provider in another state and are relocating to California cannot simply transfer that prescription to a California pharmacy. California Business and Professions Code section 4071 permits transfer of prescriptions for non-controlled medications between pharmacies, but the prescriber of record must hold a valid California license 24. An out-of-state prescription for a compounded drug is not valid in California because compounding requires a California-licensed prescriber's order.

The practical path for a relocating patient is to establish care with a California-licensed provider (telehealth or in-person), provide previous lab results if drawn within 90 days, and obtain a new California prescription. Most telehealth platforms can complete this process within 5 to 10 business days of receiving prior records.

Comparing Enclomiphene to Other Secondary Hypogonadism Treatments in California

Enclomiphene is not the only option for secondary hypogonadism. California prescribers and patients should understand how the alternatives compare.

Generic clomiphene citrate (Clomid generic): FDA-approved for ovulatory dysfunction in women, commonly used off-label in men. Widely available at retail pharmacies. Lower cost per month ($15 to $40 generic). Contains both isomers; zuclomiphene accumulates with long-term use, which may worsen estrogenic side effects 25. Some clinicians prefer enclomiphene specifically to avoid this accumulation.

hCG (human chorionic gonadotropin): Acts on testicular LH receptors to stimulate testosterone directly. Preserves testicular volume and spermatogenesis. Requires subcutaneous injection. Available through 503A pharmacies in California 26. Often combined with enclomiphene in fertility-preserving TRT protocols.

Exogenous testosterone (TRT): Suppresses LH and FSH, typically reduces sperm concentration to near-zero within 3 months 27. Not appropriate for men who want to preserve fertility. Testosterone cypionate and enanthate are FDA-approved and widely covered by California insurance plans.

The 2018 Endocrine Society guideline states: "We suggest offering treatment with testosterone to men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and improve their sexual function, body composition, muscle strength, and bone mineral density" 28. Men who prefer to maintain fertility potential or testicular function should discuss enclomiphene or hCG with their prescriber before starting TRT.

Monitoring and Safety During Enclomiphene Therapy

Enclomiphene carries a manageable side effect profile in published trials. Kim et al. (2016) reported no serious adverse events at 12.5 mg or 25 mg over 12 weeks; the most common complaints were mild headache (8%) and transient visual symptoms (4%), similar to rates seen with racemic clomiphene 29. Any visual disturbance should prompt immediate discontinuation and ophthalmologic evaluation, consistent with the prescribing caution in racemic clomiphene labeling 30.

Estradiol elevation is the most common lab abnormality. Because enclomiphene raises testosterone, peripheral aromatization to estradiol rises as well. Estradiol values above 40 to 50 pg/mL on an LC-MS/MS assay may warrant dose reduction or short-term aromatase inhibitor use 31. Hematocrit should be checked at 3 months because rising testosterone, even from endogenous production, can stimulate erythropoiesis; a hematocrit above 54% is a reason to hold or reduce therapy per AUA 2018 guidance 32.

PSA should be measured at baseline and at 3 to 6 months in men 40 years or older. Enclomiphene raises endogenous testosterone rather than delivering supraphysiologic exogenous doses, so erythrocytosis risk may be lower than with injectable TRT, though no large randomized controlled trial has directly compared these outcomes head-to-head 33.

A standard California follow-up schedule for enclomiphene:

• Week 4 to 6: Total testosterone, free testosterone, estradiol, LH, FSH
• Month 3: All of the above plus CBC, CMP, PSA (if age 40 or older)
• Month 6: Repeat full panel; reassess symptoms with validated tool such as ADAM questionnaire or AMS scale
• Annually: Full panel, bone density consideration if long-term use 34

Practical Cost and Turnaround Summary for California Patients

Most California men who qualify for enclomiphene can complete the intake-to-prescription process in 5 to 10 business days through a telehealth platform, assuming labs are drawn promptly. In-person endocrinology or urology referrals often carry 4 to 12 week wait times in major California metros, making telehealth the faster path for most patients 35. The total first-month cost typically breaks down as follows:

• Telehealth consultation: $50 to $150 (often waived with subscription plans)
• Lab draw (if not covered by insurance): $80 to $200 depending on panel
• 30-day compounded enclomiphene 12.5 mg to 25 mg: $80 to $160
• Follow-up visit at 4 to 6 weeks: $30 to $75

Patients with Medi-Cal or commercial insurance covering labs and telehealth visits may pay significantly less. Men with Covered California plans should confirm their plan's telehealth benefit tier before scheduling 36.